Market News / Story
Novartis AG (NOT) Wins FDA Approval for Rhapsido in Symptomatic Dermographism
·
Novartis said the FDA approved Rhapsido (remibrutinib) as the first treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines, expanding its use beyond chronic spontaneous urticaria. Material Details #DetailAI Analyst View1FDA approves Rhapsido for SDRegulatory win expands addressable market beyond CSU; first FDA-approved SD therapy.2Only drug approved for CSU and SDDifferentiates product vs. rivals; could support uptake and…